PharmaTelevision - Sunil Shah discusses the recent acquisition of O2H by the Indian company Piramal

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Sunil Shah discusses the recent acquisition of O2H by the Indian company Piramal

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Sunil Shah, CEO of O2h

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Origins and business of O2h

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioTrinity 2011. On this show I have Sunil Shah, who is CEO of a company called O2h based in the UK, welcome.

Sunil Shah:

Thank you for inviting me.

Fintan Walton:

Sunil, your company O2h could you tell us first of all a little bit about the origins of that company, I know you are one of the founders of that business as an entrepreneur tell us what motivated you and what were the drivers for you to set this business up?

Sunil Shah:

So actually this is my second start-up, so my first start-up was 00.00.52 I was just leaving business school and at that time although had a pharma background a biotech background I wanted to give something more entrepreneurial and at that time natural thing was to do moving into that business because it was kind of dot com boom, so I started actually called up my brother who was 00.01.07 at that as I come towards the end of my MBA and I said do you fancy doing something more entrepreneurial and he said let me just think about it and he came home one day evening said ok I have quit my job what next so he actually spent the next three months bringing for different ideas, so we started our first company and then we grew it to a certain level then the dot com crash happened we worked through it, but we learnt a lot of our business lessons in the first business so even though wasn't very successful in terms of you know a financial success although it was actually high rated an eBay at one point and so it did have there some credibility, but we used a lot of those lessons that we learnt for our next business that we wanted to make a business that was back into life sciences, we wanted to make a business profitable from day one, we wanted to make a business that didn't rely on venture funding and so on.

Fintan Walton:

What there were the lessons these were the lessons that you learnt?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Sunil Shah

CEO

Sunil Shah is the CEO of O2h. He was previously the Director of Business Development at Cambridge Biotechnology (now Biovitrum). He has consulted into a range of biotechnology companies and major pharmaceuticals such as Pfizer, GSK, and BASF via Private consulting and the Life Sciences group of PA-Consulting. Prior to co-founding O2h, he was the co-founder and Director of a technology company. The Non Executive board positions he holds include those with Opal Drug Discovery Ltd and IOTA Pharmaceuticals Ltd. He holds an MBA from Cambridge University and a BSc in Biochemistry and is a member of the Royal Society of Chemistry.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

O2h

O2h is a 5 year old discovery services company co-located in Cambridge, UK and Ahmedabad, India. The Indian operations provide a high level of chemistry expertise while UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME.